sabatolimab + spartalizumab + decitabine

sabatolimab + spartalizumab + decitabine is a combination therapy consisting of two investigational monoclonal antibodies and a hypomethylating agent, studied primarily for hematologic malignancies such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). **Sabatolimab** is a humanized monoclonal antibody targeting the **T-cell immunoglobulin and mucin domain-3 (TIM-3)**, modulating immune responses and potentially enhancing anti-tumor activity[4][6]. **Spartalizumab** is a humanized monoclonal antibody directed against **programmed death-1 (PD-1)**, functioning as an immune checkpoint inhibitor to boost T-cell activity against cancer[1][6]. **Decitabine** is a small molecule **DNA methyltransferase inhibitor** (hypomethylating agent) used in the treatment of myeloid malignancies by inducing DNA hypomethylation leading to re-expression of silenced genes and apoptosis[1]. The combination has been tested in multiple phase 1 and 2 clinical trials for its safety and efficacy primarily by Novartis[1][4][7].